Perspectives of using microRNA-loaded nanocarriers for epigenetic reprogramming of drug resistant colorectal cancers

Sukocheva, Olga; Liu, Junqi; Neganova, Margarita E.; Beeraka, Narasimha M; Aleksandrova, Yulia R.; Manogaran, Prasath; Grigorevskikh, Ekaterina M.; Chubarev, Vladimir N.; Fan, Ruitai

doi:10.1016/j.semcancer.2022.05.012

Cited by 25 publications

(21 citation statements)

References 339 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Previous researches have indicated a downregulation of miR-149-5p in colorectal cancer (CRC), suggesting its role as a tumor suppressor. 24,25 Our study contributed to this understanding by revealing a significant decrease in the expression levels of both miR-149-3p and miR-149-5p in the inflamed areas of IBD patients compared to tissue controls, which was mirrored by significantly decreased serum levels in IBD patients compared to healthy controls. This compelling evidence strongly suggests that the downregulation of miR-149-3p and miR-149-5p could be closely associated with the pathogenesis of IBD.…”

Section: Discussionmentioning

confidence: 67%

Tissue and serum miR‐149‐3p/5p in hospitalized patients with inflammatory bowel disease: Correlation with disease severity and inflammatory markers

Luo,

Chen

2023

The Kaohsiung J of Med Scie

View full text Add to dashboard Cite

This study aimed to investigate the expression levels of tissue and serum miR‐149‐3p and miR‐149‐5p in hospitalized patients with inflammatory bowel disease (IBD). A total of 35 ulcerative colitis (UC) patients, 12 Crohn's disease (CD) patients, and 25 healthy controls were included in the study. The miRNAs expressions were measured in tissue and serum samples using quantitative real‐time polymerase chain reaction (qRT‐PCR). Inflammatory biomarkers were measured, including serum albumin, erythrocyte sedimentation rate (ESR), C‐reactive protein (CRP), tumor necrosis factor‐α (TNF‐α), and interleukin‐6 (IL‐6), and fecal calprotectin. MiR‐149‐3p and miR‐149‐5p were significantly decreased in the inflamed areas of both CD and UC patients compared to tissue controls, which was consistent with decreased serum levels in IBD patients compared to healthy controls. When distinguishing UC patients from healthy controls, serum miR‐149‐3p showed 74% sensitivity and 96% specificity, while serum miR‐149‐5p exhibited 63% sensitivity and 96% specificity. In the CD versus healthy control comparison, miR‐149‐3p achieved 100% sensitivity and 96% specificity, while miR‐149‐5p demonstrated 92% sensitivity and 96% specificity. In the UC versus CD comparison, miR‐149‐5p showed 75% sensitivity and 77% specificity, while miR‐149‐3p displayed 67% sensitivity and 80% specificity. Significant correlations were identified between the tissue and serum expression of miR‐149‐3p/5p and disease activity scores, as well as inflammatory biomarkers in both CD and UC patients. Decreased expression of miR‐149‐3p and miR‐149‐5p is associated with disease activity in IBD patients. These miRNAs demonstrate diagnostic potential and may serve as biomarkers for monitoring disease activity in IBD.

show abstract

Section: Discussionmentioning

confidence: 67%

Tissue and serum miR‐149‐3p/5p in hospitalized patients with inflammatory bowel disease: Correlation with disease severity and inflammatory markers

Luo,

Chen

2023

The Kaohsiung J of Med Scie

View full text Add to dashboard Cite

show abstract

“…miR-509-3-5p is a tumor suppressor that is downregulated in lung and gastric cancers [36,37]. miR-30c-2-3p is downregulated in clear cell renal cell carcinoma [38], while miR-138-5p and miR-139-5p suppress cell growth and invasion in many solid and hematological neoplasms [39,40]. miR-190a-5p expression is decreased in squamous cell lung carcinoma [41], miR-378a-3p in uences carcinogenesis of epithelial-mesenchymal transition [42], and miR-378d and miR-378f are downregulated in colorectal carcinoma [43].…”

Section: Discussionmentioning

confidence: 99%

Integrative Transcriptomic Profiling Reveals Novel Biomarkers in Wilms Tumor

Avčin,

Črepinšek,

Bizjan

et al. 2023

Preprint

View full text Add to dashboard Cite

Background: This study aimed to identify relevant transcriptomic universal biomarkers for Wilms tumor, the most common pediatric kidney cancer, independent of the histological type and stage. Methods: Using next-generation sequencing, we analyzed the miRNA profiles of 74 kidney samples, which were divided into two independent groups: fresh frozen tissue and formalin-fixed paraffin-embedded tissue samples. Subsequent mRNA expression profiling and pathway analysis were performed to define the interplay and potential involvement of miRNAs and mRNA in Wilms tumor. Results: Comparative analysis revealed 41 differentially expressed miRNAs, with 27 miRNAs having decreased expression and 14 miRNAs having increased expression in Wilms tumor tissue compared to healthy kidney tissue. Among global mRNA transcriptomic profile differences, cross-sectional analysis suggested only a limited list of genes potentially regulated by differentially expressed miRNAs in Wilms tumor. Conclusions: Overall, our study is the first to determine the complete comprehensive miRNA and mRNA profiling of Wilms tumor using a multi-omics next-generation sequencing and bioinformatics approach, providing better insights into Wilms tumor pathogenesis. Identified universal Wilms tumor miRNAs have clear potential as biomarkers for the diagnosis and treatment of Wilms tumor, regardless of histological subtype and disease stage.

show abstract

“…The latter is based on the silencing of oncogenes or the induction of tumor suppressor genes that may be reactivated in tumor cells via miRNA-based treatment ( Figure 4 ). 128 Due to their chemical, optical, and physical properties, including targeted drug delivery, increased interaction with target cells, improved cell penetration, and controlled drug release, the nanoscale diamond particles, known as nanodiamonds (NDs), have attracted high attention since the late 1990s. The effectiveness and safety of NDs were recently proven in mouse models, where ND-doxorubicin (ND-DOX) complexes were used to treat different cancer types.…”

Section: Mirna-nps In Crc Theranosticsmentioning

confidence: 99%

“… 136 Recent evidence suggests that thioketal (TK) NPs formed by poly-(1,4-phenyleneacetone dimethylene TK) delivering siRNA against TNF-α, reduced cytokine-derived colon inflammation. 128 The encapsulation of metformin in lecithin and chitosan NPs sensitized CRC cells to metformin. The latter effect was due to the downregulation of long non-coding RNA (lncRNAs) LINC00641 and miR-21.…”

Section: Mirna-nps In Crc Theranosticsmentioning

confidence: 99%

MicroRNA-nanoparticles against cancer: Opportunities and challenges for personalized medicine

Martino¹,

Anastasio²,

Abate³

et al. 2023

Molecular Therapy - Nucleic Acids

View full text Add to dashboard Cite

Perspectives of using microRNA-loaded nanocarriers for epigenetic reprogramming of drug resistant colorectal cancers

Cited by 25 publications

References 339 publications

Tissue and serum miR‐149‐3p/5p in hospitalized patients with inflammatory bowel disease: Correlation with disease severity and inflammatory markers

Tissue and serum miR‐149‐3p/5p in hospitalized patients with inflammatory bowel disease: Correlation with disease severity and inflammatory markers

Integrative Transcriptomic Profiling Reveals Novel Biomarkers in Wilms Tumor

MicroRNA-nanoparticles against cancer: Opportunities and challenges for personalized medicine

Contact Info

Product

Resources

About